| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $11,884 | 1 | 17 |
Sells | $462,964 | 5 | 83 |
| Craig Adam R | Executive Chairman | 1 | $11,884 | 1 | $210,829 | $-198,946 |
| Volpone John | President | 0 | $0 | 1 | $109,228 | $-109,228 |
| KIRSKE DAVID | Chief Financial Officer | 0 | $0 | 3 | $142,907 | $-142,907 |
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, …
Over the last 12 months, insiders at X4 Pharmaceuticals, Inc. have bought $11,884 and sold $462,964 worth of X4 Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at X4 Pharmaceuticals, Inc. have bought $78,392 and sold $414,587 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Craig Adam R (Executive Chairman) — $11,884.
The last purchase of 4,600 shares for transaction amount of $11,884 was made by Craig Adam R (Executive Chairman) on 2026‑10‑16.
| 2026-10-16 | Craig Adam R | Executive Chairman | 4,600 0.0046% | $2.58 | $11,884 | +25.29% | ||
| 2026-10-01 | Sale | KIRSKE DAVID | Chief Financial Officer | 11,767 0.0094% | $2.86 | $33,658 | +2.83% | |
| 2026-08-12 | Sale | Craig Adam R | Executive Chairman | 47,436 0.0521% | $4.44 | $210,829 | -21.79% | |
| 2026-08-12 | Sale | Volpone John | President | 24,576 0.027% | $4.44 | $109,228 | -21.79% | |
| 2026-06-30 | Sale | KIRSKE DAVID | Chief Financial Officer | 8,543 0.0083% | $4.26 | $36,428 | -19.49% | |
| 2026-05-12 | Sale | KIRSKE DAVID | Chief Financial Officer | 16,961 0.1471% | $4.29 | $72,820 | -8.76% | |
| 2025-10-23 | Craig Adam R | Executive Chairman | 86,206 0.7092% | $2.90 | $249,997 | +26.21% | ||
| 2025-05-16 | Baldry Mark | Chief Commercial Officer | 1,032 0.0152% | $2.48 | $2,561 | +23.97% | ||
| 2025-01-24 | Sale | Ragan Paula | President and CEO | 76,473 0.0441% | $0.45 | $34,719 | -74.46% | |
| 2025-01-24 | Sale | DiBiase Mary | Chief Operating Officer | 22,258 0.0128% | $0.45 | $10,094 | -74.46% | |
| 2025-01-24 | Sale | Baldry Mark | Chief Commercial Officer | 29,159 0.0168% | $0.45 | $13,241 | -74.46% | |
| 2025-01-24 | Sale | Arbet-Engels Christophe | Chief Medical Officer | 11,624 0.0067% | $0.45 | $5,284 | -74.46% | |
| 2025-01-24 | Sale | Mostafa Adam S. | Chief Financial Officer | 74,773 0.0431% | $0.45 | $33,947 | -74.46% | |
| 2024-11-15 | Sale | Ragan Paula | President and CEO | 31,897 0.0186% | $0.39 | $12,583 | -68.04% | |
| 2024-11-15 | Baldry Mark | Chief Commercial Officer | 13,404 0.0068% | $0.34 | $4,598 | -68.04% | ||
| 2024-10-15 | Sale | Ragan Paula | President and CEO | 31,897 0.0161% | $0.56 | $17,926 | -63.68% | |
| 2024-10-07 | Sale | Ragan Paula | President and CEO | 239,436 0.1183% | $0.55 | $131,522 | -59.93% | |
| 2024-10-07 | Sale | DiBiase Mary | Chief Operating Officer | 67,695 0.0345% | $0.57 | $38,329 | -59.93% | |
| 2024-10-07 | Sale | Taveras Arthur | Chief Scientific Officer | 76,920 0.0389% | $0.56 | $43,306 | -59.93% | |
| 2024-10-07 | Sale | Baldry Mark | Chief Commercial Officer | 11,127 0.0059% | $0.58 | $6,506 | -59.93% |
| Craig Adam R | Executive Chairman | 333251 0.3361% | $1.06M | 2 | 1 | +26.21% |
| GORDON CARL L | 1868966 1.8851% | $5.92M | 1 | 0 | ||
| Ross Michael Jay | 1868961 1.885% | $5.92M | 1 | 0 | ||
| SVLSF V, LLC | 10 percent owner | 1868961 1.885% | $5.92M | 1 | 0 | |
| MCGUIRE TERRANCE | 1803429 1.819% | $5.72M | 1 | 0 | ||
| Polaris Venture Management Co. V, L.L.C. | 10 percent owner | 1803429 1.819% | $5.72M | 1 | 0 | |
| NeoMed Innovation V L.P. | 10 percent owner | 867639 0.8751% | $2.75M | 1 | 0 | |
| Nessi Claudio | director | 867639 0.8751% | $2.75M | 1 | 0 | |
| Gerngross Tillman U. | director | 392821 0.3962% | $1.25M | 1 | 0 | |
| EMBL Technology Fund II GmbH & Co. KG | 10 percent owner | 370454 0.3736% | $1.17M | 1 | 0 | |
| WYZGA MICHAEL S | director | 76667 0.0773% | $243,034.39 | 1 | 0 | <0.0001% |
| Baldry Mark | Chief Commercial Officer | 25337 0.0256% | $80,318.29 | 3 | 3 | <0.0001% |
$64,733,831 | 40 | 5.69% | $299.32M | |
$140,595,157 | 34 | 17.93% | $301.23M | |
$2,471,510 | 19 | 17.33% | $334.18M | |
$104,171,521 | 16 | 20.21% | $275.53M | |
$10,399,379 | 13 | 13.60% | $302.03M |
| Increased Positions | 60 | +166.67% | 75M | +465.54% |
| Decreased Positions | 12 | -33.33% | 2M | -12.02% |
| New Positions | 43 | New | 49M | New |
| Sold Out Positions | 4 | Sold Out | 1M | Sold Out |
| Total Postitions | 84 | +133.33% | 89M | +453.52% |
| Bain Capital Life Sciences Investors, Llc | $9,478.00 | 2.8% | 2.44M | +2M | +332.13% | 2025-09-30 |
| Nea Management Company, Llc | $8,689.00 | 2.57% | 2.23M | +2M | +347.14% | 2025-09-30 |
| Bvf Inc/Il | $8,689.00 | 2.57% | 2.23M | +2M | New | 2025-09-30 |
| Nantahala Capital Management, Llc | $8,668.00 | 2.56% | 2.23M | +2M | New | 2025-09-30 |
| Rosalind Advisors, Inc. | $6,009.00 | 1.78% | 1.54M | +2M | New | 2025-09-30 |
| Deep Track Capital, Lp | $4,366.00 | 1.29% | 1.12M | +1M | New | 2025-09-30 |
| Stonepine Capital Management, Llc | $4,109.00 | 1.21% | 1.06M | +1M | New | 2025-09-30 |
| Kingdon Capital Management, L.L.C. | $3,631.00 | 1.07% | 933,332 | +700,000 | +300% | 2025-09-30 |
| Stempoint Capital Lp | $2,161.00 | 0.64% | 555,411 | +555,411 | New | 2025-09-30 |
| Vanguard Group Inc | $1,597.00 | 0.47% | 410,485 | +178,593 | +77.02% | 2025-09-30 |